Genital Human Papilloma Virus Infection
Conditions
Keywords
HPV, cervix
Brief summary
This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV) infection. * Primary endpoint: significant drop in viral load AV2-DM versus placebo * Secondary endpoint:the number of patients with adverse events
Interventions
DRUGtopical application cervical spray
one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
DRUGtopical spray on the cervix
one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
PROCEDUREcervical swab with Cervex-Brush-Combi at T0
PROCEDUREcervical swab with Cervex-Brush-Combi at T1
Sponsors
Cesa Projects International
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
25 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
1. Women between 25 and 40 years 2. Patient has been recently (up to 6 months) Quantitatively (Viral Load) and Qualitatively (HPV types) diagnosed with HPV. 3. Ability and willingness to participate in the study. 4. Subject agrees to refrain from using prescription or supplemental antiviral medications without obtaining permission of the Treating Doctor. 5. Voluntary written informed consent.
Exclusion criteria
1. Subject has been vaccinated against HPV 2. Interval between a delivery and T0 is less than 3 months 3. Subject has a gynecologic surgical intervention between T0 and T1 4. Subject is diagnosed HPV negative at T0 5. Subject has a (adeno)carcinoma in situ. 6. Females with child bearing potential who are not using a reliable, medically accepted method of birth control 7. Pregnant or breast-feeding female, or women planning to become pregnant during the trial. 8. Medical history of immunosuppression by radiotherapy, chemotherapy, immuno-modulatory drugs, or HIV. 9. Participation to another clinical trial concerning HPV infections within 6 months before the application of AV2-DM antiviral spray. 10. Medical history of any severe diseases like hepatitis, renal or liver dysfunction, car-diovascular, gastrointestinal, malignant tumor(s), or psychiatric disorders etc., which might influence the assessments or conduct of the trial by the discretion of the investigator. 11. Intake or application of antivirals or other prohibited concomitant medication within 30 days prior to application of AV2, or patients who plan to take such drugs during the trial. 12. Known or suspected allergic or adverse response to the investigational product AV2-DM Antiviral spray, it's components, olive oil or d-limonene. 13. Inability to follow the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy comparison number of patients with drop (min 2 Log units) in HPV specific viral load AV2-DM versus placebo | 90 days |
Secondary
| Measure | Time frame |
|---|---|
| number of adverse vents AV2-DM versus placebo | 90 days |
Countries
Belgium
Outcome results
None listed